Skip to main content
. Author manuscript; available in PMC: 2023 Jul 3.
Published in final edited form as: Sci Transl Med. 2021 May 5;13(592):eabc3196. doi: 10.1126/scitranslmed.abc3196

Figure 6. CD8+CD161+ CAR T cells improve survival outcomes in an in vivo disseminated model of PDAC.

Figure 6.

(A and B) Male SCID mice were inoculated i.p. with one million CFPAC1-luc2 cells. Five days after establishment of disease as determined by IVIS imaging, cohorts were generated by randomization and given a single administration of 2 × 106 in vitro-expanded CAR+ T cells on post-implantation day 7. Disease burden was monitored by IVIS imaging (A) and quantified (B). *p < 0.05 by one-way ANOVA with Fisher’s post-hoc analysis. C. Survival was measured over time. **p < 0.01 by log-rank (Mantel-Cox) test. One representative experiment shown. For each cohort, n=5 mice. Data are presented as means ± SEM.